Related Experiment Video

Updated: Jun 20, 2025

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

25.8K

From Challenge to Opportunity: How Shwachman-Diamond Syndrome Became a Promising Target for Therapy Development

Eszter S Hars1, Lisa J McReynolds2

  • 1Shwachman-Diamond Syndrome Alliance Inc, Woburn, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|July 22, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Experiment Videos

Last Updated: Jun 20, 2025

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

25.8K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K

Articles linked to this work by shared authors, journal, and citation graph.

Genomic ascertainment of PALB2-related cancer predisposition: PALB2-related cancer predisposition.

medRxiv : the preprint server for health sciences·2026

Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy.

Blood advances·2026

Identification of biallelic POLA2 variants in two families with an autosomal recessive telomere biology disorder.

European journal of human genetics : EJHG·2024

Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts.

Leukemia·2024

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations.

Blood·2024

Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Untargeted Metabolomics Reveal New Endogenous Plasma Biomarkers Associated with CYP3A Inhibition in Humans.

Clinical pharmacology and therapeutics·2026

A Practical Guide to Implementing Real-World Evidence as Primary Basis for Approval and Label Expansion.

Clinical pharmacology and therapeutics·2026

Model-based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications.

Clinical pharmacology and therapeutics·2026

Trust, but Verify: Translating Dosing Evidence to Understudied Populations in Low- and Middle-Income Countries.

Clinical pharmacology and therapeutics·2026

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development.

Clinical pharmacology and therapeutics·2026

The Hidden Cost of QTc Assessment: A Quantitative Weight of Evidence Framework to Eliminate Structural False Positives and Restore the Lost Opportunity Cost of Abandoned Medicines.

Clinical pharmacology and therapeutics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us